PAH

March 6, 2019

Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm

Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm https://genomediscovery.org/wp-content/uploads/2019/03/Lactolose-attenuates-PAH-through-down-regulation-of-Notch-Hes1-pathway.jpg 960 720 https://genomediscovery.org/wp-content/uploads/2019/03/Lactolose-attenuates-PAH-through-down-regulation-of-Notch-Hes1-pathway.jpg March 6, 2019 March 6, 2019

What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine“[the number 1 journal in General…

January 12, 2019

Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am

Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am https://genomediscovery.org/wp-content/uploads/2019/01/Piogliazone-attenuates-Pulmonary-Arterial-Hypertension-through-down-regulation-of-Notch3-and-Hes5.jpg 960 720 https://genomediscovery.org/wp-content/uploads/2019/01/Piogliazone-attenuates-Pulmonary-Arterial-Hypertension-through-down-regulation-of-Notch3-and-Hes5.jpg January 12, 2019 January 13, 2019

What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine“[the number 1 journal in General…

November 15, 2018

Probiotic-based therapy for pulmonary arterial hypertension (PAH): Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/November/2018, 10.48 pm

Probiotic-based therapy for pulmonary arterial hypertension (PAH): Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/November/2018, 10.48 pm https://genomediscovery.org/wp-content/uploads/2018/11/Lactobacillus-Rhamnosus-attenuates-Pulmonary-Arterial-Hypertension-through-down-regulation-of-Notch3-and-Hes5.jpg 960 720 https://genomediscovery.org/wp-content/uploads/2018/11/Lactobacillus-Rhamnosus-attenuates-Pulmonary-Arterial-Hypertension-through-down-regulation-of-Notch3-and-Hes5.jpg November 15, 2018 November 15, 2018

What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General…

September 3, 2018

Chocolate your way to stay free of pulmonary arterial hypertension (PAH): Monomeric cocoa catechins, one of the components of dark chocolates, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 3/August/2018, 11.36 pm

Chocolate your way to stay free of pulmonary arterial hypertension (PAH): Monomeric cocoa catechins, one of the components of dark chocolates, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 3/August/2018, 11.36 pm https://genomediscovery.org/wp-content/uploads/2018/09/Monomeric-cocoa-catechin-attenuates-pulmonary-arterial-hypertension-through-induction-of-Notch3Hes5-pathway.png 960 720 https://genomediscovery.org/wp-content/uploads/2018/09/Monomeric-cocoa-catechin-attenuates-pulmonary-arterial-hypertension-through-induction-of-Notch3Hes5-pathway.png September 3, 2018 September 3, 2018

What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General…

August 26, 2018

Molecular therapy for pulmonary arterial hypertension (PAH): Exemestane (brand name Aromasin), a drug used to treat breast cancer, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 26/August/2018, 11.03 pm

Molecular therapy for pulmonary arterial hypertension (PAH): Exemestane (brand name Aromasin), a drug used to treat breast cancer, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 26/August/2018, 11.03 pm https://genomediscovery.org/wp-content/uploads/2018/08/Exemestane-attenuates-pulmonary-arterial-hypertension-through-induction-of-Notch3-Hes5-pathway.jpg2_.jpg 960 720 https://genomediscovery.org/wp-content/uploads/2018/08/Exemestane-attenuates-pulmonary-arterial-hypertension-through-induction-of-Notch3-Hes5-pathway.jpg2_.jpg August 26, 2018 August 26, 2018

What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine“[the number 1 journal in General…